Subscribe or Manage Preferences

ASCO 2015 - Lung Cancer

reatment options for patients with advanced squamous cell carcinoma (SCC) of the lung progressing after platinum-based chemotherapy are limited.
Tyrosine kinase inhibitors (TKIs) in advanced NSCLC increase progression-free survival (PFS), but in general do not change overall survival (OS).
Unresectable stage III NSCLC is often treated with concurrent chemoradiotherapy with poor results.
The ALK inhibitor crizotinib is more effective that first- or second-line chemotherapy in patients with advanced ALK plus NSCLC
BCD-021 has demonstrated equivalence to Avastin® (bevacizumab) in a comprehensive comparability exercise...
In a presentation by Owonikoko and colleagues, the prognostic relevance of immune checkpoint mediators in resected NSCLC was assessed.
Page 1 of 2
Results 1 - 10 of 20
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology